Tablets explicitly designed for weight reduction might be an excellent choice for those who want to get rid of excess weight in a hurry without having to make significant changes to their eating ...

Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...

The new approval that came from the USFDA makes it sure that the Linzess is safe and effective, bringing a sense of relief for parents and children with the digestive disorder condition called IBS-C.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...

– New patents expected to provide coverage for 72 mcg dose into 2031 – BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...